TY - JOUR
T1 - Lupus Anticoagulant in Systemic Lupus Erythematosus
T2 - A Clinical and Renal Pathological Study
AU - Farrugia, Emanuel
AU - Torres, Vicente E.
AU - Gastineau, Dennis
AU - Michet, Clement J.
AU - Holley, Keith E.
N1 - Funding Information:
From the Division of Nephrology and Internal Medicine, Division of Hematology and Internal Medicine, Division of Rheumatology and Internal Medicine, and Section of Medical Pathology, Mayo Clinic and Mayo Foundation, Rochester, MN. Received April 7, 1992; accepted in revised form June 30, 1992. Supported by the Mayo Clinic/Mayo Foundation. Presented at the American Society of Nephrology, 23rd Annual Meeting, Washington, DC, 1990. Address reprint requests to Vicente E. Torres, MD, Division of Nephrology, Mayo Clinic, 200 First St, SW, Rochester, MN 55905. © 1992 by the National Kidney Foundation, Inc. 0272-6386/92/2005-0004$3.00/0
PY - 1992
Y1 - 1992
N2 - Circulating lupus anticoagulant (LA) is associated with thrombosis in large and small vessels. To determine how often the presence of LA is associated with thrombosis within the renal microcirculation, 33 patients with systemic lupus erythematosus (SLE), renal dysfunction, and LA were identified over a 25-year period (LA group) and 32 patients with renal SLE but with normal gross coagulation screen were matched for age, sex, and biopsy timing (C group). Prevalences of serositis, neuropsychiatric illness, leukopenia, thrombocytopenia, hemolysis, anti-DS-DNA elevation, and complement reduction were similar. Arthritis was less and biologic false-positive (BFP) syphilis serology more common in LA. More LA patients had thrombotic events (LA 39% v C 13%; P = 0.014); bleeding episodes, including postbiopsy, were similar. At biopsy, hypertension (LA 55%, C 41 %), serum creatinine (mean ± SD: LA 186 ± 168 μmol/ L [2.1 ± 1.9 mg/dL] v C 150 ± 168 μmol/L [1.7 ± 1.9 mg/dL]) and proteinurla (LA 2.6 ± 3.1 g/24 h v C 3.1 ± 2.7) were similar. Lesions by World Health Organization (WHO) class, activity, and chronicity indices, as well as immunofluorescence (IF) and electron microscopy (EM) findings, were not significantly different. Occlusive glomerular, arteriolar, and arterial fibrin thrombi, along with varying degrees of renal thrombotic microangiopathy, were seen in five of 33 patients with LA, but zero of 32 C patients (P = 0.053); three of these five patients died soon after biopsy. Overall, mortality was not different between LA and C. We conclude that the majority of patients with SLE, renal dysfunction, and LA exhibit renal morphologic findings indistinguishable from patients without LA. However, a significant minority of LA patients have thrombotic microangiopathy in their biopsy, which is accompanied by a worse prognosis.
AB - Circulating lupus anticoagulant (LA) is associated with thrombosis in large and small vessels. To determine how often the presence of LA is associated with thrombosis within the renal microcirculation, 33 patients with systemic lupus erythematosus (SLE), renal dysfunction, and LA were identified over a 25-year period (LA group) and 32 patients with renal SLE but with normal gross coagulation screen were matched for age, sex, and biopsy timing (C group). Prevalences of serositis, neuropsychiatric illness, leukopenia, thrombocytopenia, hemolysis, anti-DS-DNA elevation, and complement reduction were similar. Arthritis was less and biologic false-positive (BFP) syphilis serology more common in LA. More LA patients had thrombotic events (LA 39% v C 13%; P = 0.014); bleeding episodes, including postbiopsy, were similar. At biopsy, hypertension (LA 55%, C 41 %), serum creatinine (mean ± SD: LA 186 ± 168 μmol/ L [2.1 ± 1.9 mg/dL] v C 150 ± 168 μmol/L [1.7 ± 1.9 mg/dL]) and proteinurla (LA 2.6 ± 3.1 g/24 h v C 3.1 ± 2.7) were similar. Lesions by World Health Organization (WHO) class, activity, and chronicity indices, as well as immunofluorescence (IF) and electron microscopy (EM) findings, were not significantly different. Occlusive glomerular, arteriolar, and arterial fibrin thrombi, along with varying degrees of renal thrombotic microangiopathy, were seen in five of 33 patients with LA, but zero of 32 C patients (P = 0.053); three of these five patients died soon after biopsy. Overall, mortality was not different between LA and C. We conclude that the majority of patients with SLE, renal dysfunction, and LA exhibit renal morphologic findings indistinguishable from patients without LA. However, a significant minority of LA patients have thrombotic microangiopathy in their biopsy, which is accompanied by a worse prognosis.
KW - Systemic lupus erythematosus
KW - lupus anticoagulant
KW - renal thrombotic microangiopathy
UR - http://www.scopus.com/inward/record.url?scp=0026462946&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026462946&partnerID=8YFLogxK
U2 - 10.1016/S0272-6386(12)70258-5
DO - 10.1016/S0272-6386(12)70258-5
M3 - Article
C2 - 1442758
AN - SCOPUS:0026462946
SN - 0272-6386
VL - 20
SP - 463
EP - 471
JO - American Journal of Kidney Diseases
JF - American Journal of Kidney Diseases
IS - 5
ER -